Alzheimer's disease biological PET staging using plasma p217+tau.

ABSTRACT:

Background

Plasma phospho-tau biomarkers, such as p217+tau, excel at identifying Alzheimer's disease (AD) neuropathology. However, their ability to substitute for tau PET to identify AD biological stage is unclear.

Methods

Participants included 248 cognitively unimpaired (CU) and 227 cognitively impaired (CI) individuals, with Janssen plasma p217+tau Simoa® assay, ¹⁸F-NAV4694 Aβ-PET (A) and ¹⁸F-MK6240 tau-PET (T) data. Biological PET stages were defined according to the Revised Criteria for Diagnosis and Staging of Alzheimer's Disease (2024): Initial (A + T-), Early (A + T_MTL + ), Intermediate (A + T_MOD + ), and Advanced (A + T_HIGH + ). The threshold for A+ was 25 Centiloid and for T_HIGH + , the 75th percentil

SUBMITTER: Feizpour A 

PROVIDER: S-EPMC11868538 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature